Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion

Tasly Biopharma Files for Hong Kong IPO That Could Raise $1 Billion

Tasly Biopharma of Shanghai has filed a prospectus for a Hong Kong IPO. The transaction, which has been expected for the past year, could raise as much as $1 billion. Tasly Bio is the biologics arm of Tasly Pharma, a TCM company that decided in...

Read more
MicroPort Orthopedics Launches Improved Knee Replacement Product

MicroPort Orthopedics Launches Improved Knee Replacement Product

MicroPort Orthopedics, a US division of Shanghai’s medical device maker, MicroPort Scientific, launched the Evolution® NitrX™ Medial-Pivot Knee System, the latest version of its knee replacement product. The newest NitrX™ product features a...

Read more
Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

Eli Lilly Unit Selects China’s Amoy Diagnostics’ Gene Products for Cancer Drug

China’s Amoy Diagnostics will partner with Loxo Oncology, a developer of targeted cancer drugs owned by Eli Lilly and Company, to supply it with accompanying reagents for genetic diagnosis during clinical trials of new drugs in Asia. The...

Read more
Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...

Read more
PwC says US companies are expected to spend 6% more on employee health care next year as drug prices rise

PwC says US companies are expected to spend 6% more on employee health care next year as drug prices rise

Employer medical costs are projected to rise by 6% next year, according to PwC. The rate of increase is a four-year high, due in part to rising drug prices. The jump is attributed to expensive specialty drugs that weren’t available a few years...

Read more
Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare

Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare

Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California...

Read more
dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings

dMed, a Shanghai Clinical CRO, Opens Washington Office for US FDA Filings

dMed Biopharma, a Shanghai clinical CRO, has opened a Washington office to help China biopharmas complete their US regulatory filings. Since 2017, China’s harmonization with the regulatory systems of other countries revolutionized the...

Read more
Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

Gilead Strikes $2.48 Billion Deal with Nurix to Focus on Protein Degradation

Gilead Sciences and Nurix, based in Forest City, Calif. and San Francisco, respectively, signed a global strategic collaboration deal that could hit $2.48 billion. The focus will be on discovering drugs that use the body’s natural protein control...

Read more
Cellular Bio Starts Phase I China Trial of CD20 CAR-T

Cellular Bio Starts Phase I China Trial of CD20 CAR-T

Cellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell...

Read more
CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate

CARsgen Given Green Light for US Trials of BCMA CAR-T Candidate

CARsgen Therapeutics, a Shanghai CAR-T company, was approved to start US trials of its fully human BCMA (B-Cell Maturation Antigen)-CAR-T therapy for patients with relapsed/refractory multiple myeloma. Four months ago, China’s NMPA approved...

Read more
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks...

Read more
CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...

Read more
Do NOT follow this link or you will be banned from the site!